SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 154-163

  Djang, David S W ^a   Janssen, Marcel J R ^b   Bohnen, Nicolaas ^c   Booij, Jan ^d   Henderson, Theodore A ^e   Herholz, Karl ^f   Minoshima, Satoshi ^g   Rowe, Christopher C ^h   Sabri, Osama ⁱ   Seibyl, John ^j   Van Berckel, Bart N M ^k   Wanner, Michele ^g  

^a Seattle Nuclear Medicine   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e Synaptic Space   (United States)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF WASHINGTON   (United States)

^h AUSTIN HOSPITAL   (Australia)

ⁱ UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^j INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^k VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; IOFLUPANE I 123; LUGOL; POTASSIUM IODIDE; POTASSIUM PERCHLORATE;

CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DIZZINESS; DRUG BINDING; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; EARLY DIAGNOSIS; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INFORMATION DISSEMINATION; INFORMATION PROCESSING; INJECTION SITE REACTION; LICENSING; MEDICAL DOCUMENTATION; MEDICAL EDUCATION; MEDICAL HISTORY; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL SOCIETY; NAUSEA; PARKINSONISM; PATIENT CARE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RADIATION DOSE; RADIATION EXPOSURE; REGISTRATION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TOTAL QUALITY MANAGEMENT; TREMOR; VERTIGO; XEROSTOMIA;

DOCUMENTATION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; NORTROPANES; NUCLEAR MEDICINE; PREGNANCY; RESEARCH DESIGN; SOCIETIES, MEDICAL; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84855378721     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.100784     Document Type: Review

References (47)

1. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing. 1999;28:99-102. (Pubitemid 29161211)
2. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 2001;57(suppl 3):S34-S38.
3. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18:1415-1423. (Pubitemid 38035363)
4. Catafau AM. Brain SPECT of dopaminergic neurotransmission: a new tool with proved clinical impact. Nucl Med Commun. 2001;22:1059-1060. (Pubitemid 33015969)
5. 123I]FP-CIT SPECT imaging. Mov Disord. 2000;15:503-510.
6. Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-1884. (Pubitemid 28518886)
7. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord. 2007;22:1229-1238. (Pubitemid 47325028)
8. 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol. 2008;59:258-266.
9. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol. 2007;7:27.
10. 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15:692-698.
11. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. 2003;18(suppl. 7):S43-S51. (Pubitemid 37336928)
12. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62:133-140.
13. Ponsen MM, Stoffers D, Wolters ECh, Booij J, Berendse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010;81:396-399.
14. 123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord. 2006;21:510-514.
15. Felicio AC, Godeiro-Junior C, Moriyama TS, et al. Degenerative parkinsonism in patients with psychogenic parkinsonism: a dopamine transporter imaging study. Clin Neurol Neurosurg. 2010;112:282-285.
16. 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
17. 123I-FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176-1181.
18. Carroll FI, Scheffel U, Dannals RF, Boja JW, Kuhar MJ. Development of imaging agents for the dopamine transporter. Med Res Rev. 1995;15:419-444.
19. 125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol. 1997;24:629-634.
20. Abi-Dargham A, Gandelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med. 1996;37:1129-1133. (Pubitemid 26329519)
21. 123I beta-CIT, Dopascan injection, GPI 200, RTI 55. Drugs R D. 2003;4:320-322.
22. DaTscan prescribing information. Available at: http://us.datscan.com/wp- content/themes/main-site/pdf/prescribing-information.pdf. Accessed October 14, 2011.
23. 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443-450.
24. 123I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35:424-438.
25. 123I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging. 2005;32:1452-1456.
26. 131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35:1039-1047.
27. Booij J, Hemelaar J, Speelman J, de Bruin K, Janssen A, van Royen E. One-day protocol for imaging of the nigrostriatal pathway in Parkinson's disease by [123I] FPCIT SPECT. J Nucl Med. 1999;40:753-761. (Pubitemid 29210748)
28. Morano GN, Seibyl JP. Technical overview of brain SPECT imaging: improving acquisition and processing of data. J Nucl Med Technol. 2003;31:191-195. (Pubitemid 47618994)
29. Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging. 2011;38:764-773.
30. Habraken JB, Booij J, Slomka P, et al. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med. 1999;40:1091-1097. (Pubitemid 29315496)
31. 123I]IPT binding to the presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med. 2000;27:1809-1812.
32. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109-1118. (Pubitemid 43741072)
33. Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240-1253. (Pubitemid 47290660)
34. Morton RJ, Guy MJ, Clauss R, Hinton PJ, Marshall CA, Clarke EA. Comparison of different methods of DatSCAN quantification. Nucl Med Commun. 2005;26: 1139-1146. (Pubitemid 41677606)
35. Zubal IG, Early M, Yuan O, Jennings D, Marek K, Seibyl JP. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. J Nucl Med. 2007;48:857-864. (Pubitemid 46909911)
36. Kas A, Payoux P, Habert MO, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med. 2007;48:1459-1467. (Pubitemid 47397396)
37. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-omega-fluoropropyl- 2β-carbomethoxy-3β-(4-iodophenyl)tropane SPECT in healthy controls and earlystage, drug-naive Parkinson's disease. J Nucl Med. 1998;39:1143-1148. (Pubitemid 28326141)
38. Catafau AM, Tolosa E. DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;19:1175-1182. (Pubitemid 39433368)
39. 123I]FP-CIT SPECT. Mov Disord. 2009;24:500-508.
40. 123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27:867-869.
41. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med. 2004;45:1688-1693.
42. 123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord. 2002; 17:518-523.
43. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med. 1998;39:1500-1508. (Pubitemid 28459875)
44. Dickson JC, Tossici-Bolt L, Sera T, et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging. 2010; 37:23-35.
45. Koch W, Radau PE, Munzing W, Tatsch K. Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom. Eur J Nucl Med Mol Imaging. 2006;33:495-502.
46. 123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004;61:1224-1229.
47. 123I]FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med. 1998;25:24-30.